eliquis apixaban logo eliquis apixaban logo eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Dosing considerations for patients with renal or hepatic impairment

Renal impairment1

Mild (CrCl 51–80 ml/min) or moderate (CrCl 30–50 ml/min) renal impairment

No dose adjustment required unless the patient fulfils criteria for dose reduction

Severe renal impairment
(CrCl 15–29 ml/min)

Dose reduction to 2.5 mg BD

Renal failure (CrCl <15 ml/min)

Not recommended

Dialysis

Not recommended


Only ELIQUIS (apixaban) is suggested as a consideration by NICE CG182 over warfarin for patients with NVAF and moderate renal impairment2

NICE CKD Clinical Guideline (CG182, 2014)2
“Consider apixaban in preference to warfarin in people with confirmed eGFR of 30–50 ml/min/1.73 m2 and NVAF who have ≥1 of the following risk factors: prior stroke or transient ischaemic attack; age ≥75; hypertension; diabetes mellitus; symptomatic heart failure”

ELIQUIS, dabigatran etexilate, rivaroxaban and VKA are all recommended by NICE Clinical Guideline 180 (NICE CG180, 2014) as anticoagulation therapy options for the prevention of stroke in patients with NVAF (in line with their respective marketing authorisations).3 Edoxaban was not considered for inclusion in either of the NICE guidelines (NICE CG180, 2014 and NICE CG182, 2014) as it did not have EU marketing authorisation at the time of publication. However, edoxaban has now received NICE Technology Appraisal guidance and is recommended as an option for preventing stroke and systemic embolism in patients with NVAF and one or more risk factors, in line with its marketing authorisations.4


Hepatic impairment1

Mild or moderate hepatic impairment
(Child-Pugh A or B)

Use with caution
No dose adjustment required

Severe hepatic impairment

Not recommended

Hepatic disease associated with coagulopathy and clinically relevant bleeding risk

Contraindicated


Patients with elevated liver enzymes ALT / AST >2 x ULN or total bilirubin ≥1.5 x ULN were excluded in clinical trials. Therefore, ELIQUIS should be used cautiously in this population. Prior to initiating ELIQUIS, liver function testing should be performed.1

Diagnosemethoden

It’s simple to switch your patients to ELIQUIS1

ELIQUIS 5 mg BD: simple dosing for stroke prevention in NVAF, with or without food

ELIQUIS dosing for your patients with DVT / PE is simple: START twice daily, STAY twice daily1


ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

ALT = Alanine Aminotransferase   
AST = Aspartate Aminotransferase   
BD = Twice Daily   
CKD = Chronic Kidney Disease   
CrCl = Creatinine Clearance   
eGFR = Estimated Glomerular Filtration Rate
NICE = National Institute for Health and Care Excellence    
NVAF = Non-Valvular Atrial Fibrillation   
ULN = Upper Limit of Normal   
VKA = Vitamin K Antagonist

References

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. NICE clinical guideline 182. Chronic kidney disease in adults: assessment and management. July 2014. Last updated January 2015. Available at http://guidance.nice.org.uk/cg182. Last accessed April 2018.
  3. NICE clinical guideline 180. Atrial fibrillation: management. June 2014. Last updated August 2014. Available at http://guidance.nice.org.uk/cg180. Last accessed April 2018.
  4. NICE technology appraisal guidance TA355. Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation. September 2015. Available at https://www.nice.org.uk/guidance/ta355. Last accessed April 2018.